Phase II trial in 114 patients with unresectable locally advanced oesophageal squamous cell carcinoma: tislelizumab with induction chemo and CRT without maintenance had better PFS than historical control (1-year 71.9% v 56.4%; HR 0.54); with maintenance it did not (HR 1.06).
RCTn = 114
Chen et al. Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)